Iovance Biotherapeutics, Inc. short interest in 2026
In 2026, Iovance Biotherapeutics, Inc.'s disclosed short interest ran from 29.50% of shares outstanding on 15 Jan 2026 to 19.23% on 15 Sep 2026, a change of -10.27 percentage points. The year's high was 31.88% on 13 Feb 2026 and its low 19.23% on 15 Sep 2026, averaging 24.90% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.61 days on 13 Feb 2026. Full history: Iovance Biotherapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 29.50% (15 Jan 2026)
- End of year
- 19.23% (15 Sep 2026)
- Change
- -10.27 pp
- High
- 31.88% (13 Feb 2026)
- Low
- 19.23% (15 Sep 2026)
- Average
- 24.90%
- Highest days to cover
- 14.61 (13 Feb 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 29.50% | 10.13 | |
| 30 Jan 2026 | 26.51% | 7.57 | |
| 13 Feb 2026 | 31.88% | 14.61 | |
| 27 Feb 2026 | 31.78% | 7.26 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 27.93% | 4.98 | |
| 31 Mar 2026 | 26.90% | 9.47 | |
| 15 Apr 2026 | 24.37% | 6.54 | |
| 30 Apr 2026 | 25.69% | 9.15 | |
| 15 May 2026 | 23.88% | 6.00 | 10-Q filed, results (8-K) |
| 29 May 2026 | 23.35% | 8.19 | |
| 15 Jun 2026 | 23.18% | 7.90 | |
| 30 Jun 2026 | 22.51% | 7.10 | |
| 15 Jul 2026 | 22.37% | 5.91 | |
| 31 Jul 2026 | 22.07% | 6.28 | |
| 14 Aug 2026 | 22.73% | 4.79 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 19.46% | 5.28 | |
| 15 Sep 2026 | 19.23% | 7.43 |
See also: Iovance Biotherapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.